School of Management, Beijing University of Chinese Medicine, Beijing, China.
Medical Device Regulatory Research and Evaluation Center, West China Hospital, Sichuan University, Chengdu, China.
BMC Health Serv Res. 2023 Jan 26;23(1):89. doi: 10.1186/s12913-023-09078-3.
As the main cause of cancer death, lung cancer imposes seriously health and economic burdens on individuals, families, and the health system. In China, there is no national study analyzing the hospitalization expenditures of different payment methods by lung cancer inpatients. Based on the 2010-2016 database of insured urban resident lung cancer inpatients from the China Medical Insurance Research Association (CHIRA), this paper aims to investigate the characteristics and cost of hospitalized lung cancer patient, to examine the differences in hospital expenses and patient out-of-pocket (OOP) expenses under four medical insurance payment methods: fee-for-service (FFS), per-diem payments, capitation payments (CAP) and case-based payments, and to explore the medical insurance payment method that can be conducive to controlling the cost of lung cancer.
This is a 2010-2016, 7-year cross-sectional study. CHIRA data are not available to researchers after 2016. The Medical Insurance Database of CHIRA was screened using the international disease classification system to yield 28,200 inpatients diagnosed with lung cancer (ICD-10: C34, C34.0, C34.1, C34.2, C34.3, C34.8, C34.9). The study includes descriptive analysis and regression analysis based on generalized linear models (GLM).
The average patient age was 63.4 years and the average length of hospital stay (ALOS) was 14.2 day; 60.7% of patients were from tertiary hospitals; and 45% were insured by FFS. The per-diem payment had the lowest hospital expenses (RMB7496.00/US$1176.87), while CAP had the lowest OOP expenses (RMB1328.18/US$208.52). Compared with FFS hospital expenses, per-diem was 21.3% lower (95% CI = -0.265, -0.215) and case-based payment was 8.4% lower (95% CI = -0.151, -0.024). Compared with the FFS, OOP expenses, per-diem payments were 9.2% lower (95% CI = -0.130, -0.063) and CAP was 15.1% lower (95% CI = -0.151, -0.024).
For lung cancer patients, per-diem payment generated the lowest hospital expenses, while CAP meant patients bore the lowest OOP costs. Policy makers are suggested to give priority to case-based payments to achieve a tripartite balance among medical insurers, hospitals, and insured members. We also recommend future studies comparing the disparities of various diseases for the cause of different medical insurance schemes.
肺癌是癌症死亡的主要原因,它给个人、家庭和医疗系统带来了严重的健康和经济负担。在中国,还没有针对不同支付方式的肺癌住院患者住院费用进行分析的全国性研究。本研究基于中国医疗保险研究会(CHIRA)2010-2016 年参保城镇居民肺癌住院患者数据库,旨在调查肺癌住院患者的特征和费用,考察四种医疗保险支付方式(按服务项目付费、按日付费、总额预付和按病种付费)下的住院费用和患者自付费用的差异,并探讨有利于控制肺癌成本的医疗保险支付方式。
这是一项 2010-2016 年的 7 年横断面研究。CHIRA 数据在 2016 年后对研究人员不可用。使用国际疾病分类系统对 CHIRA 的医疗保险数据库进行筛查,得出 28200 例被诊断为肺癌的住院患者(ICD-10:C34、C34.0、C34.1、C34.2、C34.3、C34.8、C34.9)。研究包括基于广义线性模型(GLM)的描述性分析和回归分析。
患者平均年龄为 63.4 岁,平均住院日(ALOS)为 14.2 天;60.7%的患者来自三级医院;45%的患者通过按服务项目付费。按日付费的住院费用最低(人民币 7496.00 元/美元 1176.87 元),而总额预付的自付费用最低(人民币 1328.18 元/美元 208.52 元)。与按服务项目付费的住院费用相比,按日付费低 21.3%(95%CI=-0.265,-0.215),按病种付费低 8.4%(95%CI=-0.151,-0.024)。与按服务项目付费相比,自付费用方面,按日付费低 9.2%(95%CI=-0.130,-0.063),总额预付低 15.1%(95%CI=-0.151,-0.024)。
对于肺癌患者,按日付费产生的住院费用最低,而总额预付则意味着患者自付费用最低。决策者应优先考虑按病种付费,以实现医疗保险机构、医院和参保人员三方平衡。我们还建议未来对各种疾病的差异进行研究,以确定不同医疗保险计划的原因。